Chronic Obstructive Pulmonary Disease: key endpoint results by drug

The key endpoints of Chronic Obstructive Pulmonary Disease trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Chronic Obstructive Pulmonary Disease page.

Moderate or severe exacerbations, annualised rate

Moderate or severe exacerbations, annualised rate in Chronic Obstructive Pulmonary Disease: 7 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Aclidinium bromide0.40.6−0.1wk 52 · n 1791NCT01966107 Phase 4, primary
Benralizumab0.90.9±0100 mg · wk 56.14 · n 40NCT01227278 Phase 2, primary
dupilumab0.81.0−0.2300 mg q2w · wk 52 · n 468NCT03930732 Phase 3, primary
fluticasone furoate/umeclidinium/vilanterol0.91.1 (FF/VI)—wk 52 · n 4145NCT02164513 Phase 3, primary
Mepolizumab1.41.7−0.3100 mg · wk 52 · n 233NCT02105948 Phase 3, primary
Olodaterol0.60.7−0.110 mcg qd · wk 48 · n 234NCT00796653 Phase 3, secondary
Tiotropium bromide0.91.3−0.418μg · n 54NCT01663987 Phase 4, secondary

Drugs checked with no result here: 12 trial running, 14 not reported, 9 not posted.

Trough FEV1, change

Trough FEV1, change in Chronic Obstructive Pulmonary Disease: 9 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Aclidinium bromide0.1-0.1+0.2400/12 μg · wk 24 · n 262NCT03022097 Phase 3, primary
Aclidinium bromide/formoterol fumarate0.1-0.0+0.1400/12 μg · wk 24 · n 335NCT01437397 Phase 3, primary
ensifentrine-0.0-0.0±0wk 24 · n 498NCT04542057 Phase 3, secondary
fluticasone furoate/umeclidinium/vilanterol0.1-0.0 (BUD/FOR)—100/62.5/25 µg · wk 24 · n 836NCT02345161 Phase 3, primary
Olodaterol0.0-0.1+0.110 mcg qd · wk 24 · n 228NCT00796653 Phase 3, primary
Revefenacin0.1-0.1+0.2175 mcg QD · wk 12.1 · n 105NCT05046795 Phase 3, primary
Tiotropium bromide0.10.1 (AB)—400/12 μg · wk 24 · n 314NCT02796677 Phase 3, primary
Umeclidinium0.1-0.0+0.262.5 mcg · wk 24 · n 176NCT02184611 Phase 3, primary
Umeclidinium/Vilanterol0.20.1 (TIO)—62.5/25 µg · wk 24 · n 400NCT01777334 Phase 3, primary

Drugs checked with no result here: 10 trial running, 14 not reported, 9 not posted.

SGRQ total, change

SGRQ total, change in Chronic Obstructive Pulmonary Disease: 12 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Aclidinium bromide-8.7-4.7−4400/12 μg · wk 24 · n 262NCT03022097 Phase 3, secondary
Aclidinium bromide/formoterol fumarate-6.6-2.2−4.4400/12 μg · wk 24 · n 335NCT01437397 Phase 3, secondary
astegolimab56.659.6−3wk 24 · n 42NCT03615040 Phase 2, secondary
dupilumab-9.7-6.4−3.4300 mg q2w · wk 52 · n 456NCT03930732 Phase 3, secondary
ensifentrine-4.5-4.1−0.5wk 24 · n 489NCT04542057 Phase 3, secondary
fluticasone furoate/umeclidinium/vilanterol-6.6-4.3 (BUD/FOR)—100/62.5/25 µg · wk 24 · n 846NCT02345161 Phase 3, primary
Mepolizumab-2.8-3+0.2100 mg · wk 52 · n 226NCT02105948 Phase 3, secondary
Olodaterol37.142.0−4.95 μg + 5 μg · wk 12 · n 196NCT01964352 Phase 3, primary
Revefenacin-4.80.2−5175 mcg QD · wk 12.1 · n 110NCT05046795 Phase 3, secondary
Tiotropium bromide-4.1-2.0−2.1wk 12 · n 315NCT00496470 Phase 4, secondary
tozorakimab-9.2-8.3−0.9wk 12 · n 62NCT04631016 Phase 2, secondary
Umeclidinium-6.2-2.1−462.5/25 mcg · wk 12 · n 212NCT02152605 Phase 3, primary

Drugs checked with no result here: 11 trial running, 12 not reported, 7 not posted.

TDI focal score

TDI focal score in Chronic Obstructive Pulmonary Disease: 6 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Aclidinium bromide2.92.1+0.8400/12 μg · wk 24 · n 262NCT03022097 Phase 3, secondary
Aclidinium bromide/formoterol fumarate2.00.6+1.4400/12 μg · wk 24 · n 335NCT01437397 Phase 3, secondary
ensifentrine1.90.8+1.1wk 24 · n 471NCT04535986 Phase 3, secondary
fluticasone furoate/umeclidinium/vilanterol2.31.7 (BUD/FOR)—100/62.5/25 µg · wk 24 · n 839NCT02345161 Phase 3, secondary
Olodaterol1.51.1+0.410 mcg qd · wk 24 · n 220NCT00796653 Phase 3, primary
Umeclidinium2.51.6+0.962.5 mcg · wk 24 · n 176NCT02184611 Phase 3, secondary

Drugs checked with no result here: 11 trial running, 15 not reported, 10 not posted.

  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 42 approved or late-stage drugs with a featured trial in Chronic Obstructive Pulmonary Disease were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.